Elimination Programme has started training sessions for doctors to introduce BPaL, the shortest treatment for drug-resistant TB to date. BPaL, a combination of bedaquiline, pretomanid and linezolid, ...

In a world first, researchers at the Kennedy Institute, Oxford have mapped the cellular dynamics following treatment with the ...

Some people infected with HIV are teeming with virus, but don’t get sick. Their resistive powers probably come from a mix of ...

A six-week treatment of chemotherapy before chemoradiotherapy could improve survival rates in people with cervical cancer, ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

A new study published in the Journal of Clinical Tuberculosis and Other Mycobacterial Diseases showed that two ...

Gilead and Merck said their once-weekly pill to treat HIV resulted in a comparable level of viral suppression compared to a ...

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...